Insider · CIK 0001463414
Leonard L Mazur
Files at CTXR (Citius Pharmaceuticals, Inc.), CTOR (CITIUS ONCOLOGY, INC.), CNTN (Tharimmune, Inc.). First filing -, latest -.
In brief
Leonard L Mazur files SEC Form 4 as CEO, director and 10% owner at CTXR (Citius Pharmaceuticals, Inc.), and also at CTOR (CITIUS ONCOLOGY, INC.), CNTN (Tharimmune, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Leonard L Mazur has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Dec 22, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Dec 1, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Sep 23, 2025 |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivative | -125,490 | - | - | 0 | Sep 23, 2025 |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Warrant to Purchase Common Stockderivative | +125,490 | - | - | 125,490 | Sep 23, 2025 |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivative | -89,388 | - | - | 0 | Sep 23, 2025 |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Warrant to Purchase Common Stockderivative | +89,388 | - | - | 89,388 | Sep 23, 2025 |
| Dec 12, 2024 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Dec 16, 2024 |
| Nov 7, 2024 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +600,000 | $0.00 | $0 | 600,000 | Nov 12, 2024 |
| Nov 7, 2023 | CNTN Tharimmune, Inc. | AGrant or award Options (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Nov 9, 2023 |
| Oct 10, 2023 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Option to Purchase Common Stockderivative | +550,000 | $0.00 | $0 | 550,000 | Oct 12, 2023 |
Questions about Leonard L Mazur
Answered from the filings on this page, as of the latest one.
Is Leonard L Mazur buying or selling?
Leonard L Mazur has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Leonard L Mazur's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Leonard L Mazur has 0.
Where does Leonard L Mazur file Form 4?
Leonard L Mazur has filed Form 4 at CTXR (Citius Pharmaceuticals, Inc.) as Chief Executive Officer; CTOR (CITIUS ONCOLOGY, INC.) as Chief Executive Officer; CNTN (Tharimmune, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.